Evidence map›Paper›PMID 36555698›Full record

ArticleInternational journal of molecular sciences2022

The Soluble Fms-like Tyrosine Kinase-1 Contributes to Structural and Functional Changes in Endothelial Cells in Chronic Kidney Disease.

Annika Schulz, Carolin Christina Drost, Bettina Hesse, Katrin Beul, Marcus Brand, Giovana Seno Di Marco

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Sickle Cell Disease and CKD: An Update.American journal of nephrology · 2024
    Review
  4. Article
  5. Exploring the Relationship Between Angiogenesis Inhibition of sFLT-1 and Sickle Cell Nephropathy.Nigerian medical journal : journal of the Nigeria Medical Association
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Annika SchulzDepartment of Internal Medicine D, University Hospital Münster, 48149 Münster, Germany.
Carolin Christina DrostDepartment of Internal Medicine D, University Hospital Münster, 48149 Münster, Germany.
Bettina HesseDepartment of Internal Medicine D, University Hospital Münster, 48149 Münster, Germany.
Katrin BeulDepartment of Internal Medicine D, University Hospital Münster, 48149 Münster, Germany.
Marcus BrandDepartment of Internal Medicine D, University Hospital Münster, 48149 Münster, Germany.
Giovana Seno Di MarcoDepartment of Internal Medicine D, University Hospital Münster, 48149 Münster, Germany.ORCID 0000-0002-1877-638X
University Hospital Münster · DE

Funding

Deutsche Forschungsgemeinschaft KFO342 - ZA428/18-1Deutsche Forschungsgemeinschaft SE2824/3-1
6 · The paper itself

Abstract

Endothelial cells are a critical target of the soluble Fms-like tyrosine kinase-1 (sFlt-1), a soluble factor increased in different diseases with varying degrees of renal impairment and endothelial dysfunction, including chronic kidney disease (CKD). Although the mechanisms underlying endothelial dysfunction are multifactorial and complex, herein, we investigated the damaging effects of sFlt-1 on structural and functional changes in endothelial cells. Our results evidenced that sera from patients with CKD stiffen the endothelial cell cortex in vitro, an effect correlated with sFlt-1 levels and prevented by sFlt-1 neutralization. Besides, we could show that recombinant sFlt-1 leads to endothelial stiffening in vitro and in vivo. This was accompanied by cytoskeleton reorganization and changes in the endothelial barrier function, as observed by increased actin polymerization and endothelial cell permeability, respectively. These results depended on the activation of the p38 MAPK and were blocked by the specific inhibitor SB203580. However, sFlt-1 only minimally affected the expression of stiffness-sensitive genes. These findings bring new insight into the mechanism of action of sFlt-1 and its biological effects that cannot be exclusively ascribed to the regulation of angiogenesis.

Indexed as

Pre-EclampsiaRenal Insufficiency, ChronicVascular Endothelial Growth Factor Receptor-1Endothelial CellsFemaleHumansFLT1 protein, humanVascular Endothelial Growth Factor Receptor-1chronic kidney disease (CKD)endothelial dysfunctionendothelial stiffnessFms-like tyrosine kinase-1 (sFlt-1)

Identifiers

PMID36555698
PMCPMC9787493
OpenAlexW4312210844

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.